ClinicalTrials.gg
Active, not recruitingNCT07225686MARITIME-OSA-1Updated Oct 6, 2026

Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy

A Phase 3 interventional study of Maridebart cafraglutide and Placebo in Obesity and Obstructive Sleep Apnea, sponsored by Amgen. Active, not recruiting at 61 sites in 11 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Updated Oct 6, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
250
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 28 studies testing maridebart cafraglutide in Obesity — 9 open to participants now, 17 under way, 11 of them phase 3. maridebart cafraglutide · Obesity.

Planned enrollment
15th of 28
250 · median 275
Started
2025
with 10 others
Phase 3
11 of 28
6 open now
Primary completion
2027-08
later than 7 of 16 live
Registered
10th of 28
by date
Lead sponsor
28 of 28
Amgen

Among the 28 studies testing maridebart cafraglutide in Obesity, this one is the 15th largest by planned enrollment, is one of 11 that started in 2025, is one of 11 in phase 3, reaches primary completion later than 7 of the 16 other live ones, and was the 10th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

Browse Obesity studies →

Open to participants now

9 of the 28 studies testing maridebart cafraglutide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About maridebart cafraglutide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing maridebart cafraglutide in Obesity, or all of them as a file.
02

Study summary

This Phase 3 clinical trial is designed to evaluate the efficacy and safety of maridebart cafraglutide compared to placebo over a 52-week period in adults with obstructive sleep apnea (OSA) who are receiving positive airway pressure (PAP) therapy and are living with overweight or obesity.

03

Conditions studied

  • Obesity
  • Obstructive Sleep Apnea

Keywords

  • MariTide
  • Maridebart Cafraglutide
  • AMG 133
  • Obesity
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • AHI ≥ 15 on polysomnography at day 1 before randomization.
  • ≥ 27 kg/m\^2 at screening.
  • History of at least 1 unsuccessful attempt at weight loss by diet and exercise.
  • On positive airway pressure (PAP) therapy for at least 3 consecutive months before screening and plan to continue PAP therapy during the trial.

Exclusion criteria

Exclusion Criteria:

  • Had any previous or planned upper airway surgery or major ear, nose, or throat surgery for OSA.
  • Significant craniofacial abnormalities that may affect breathing at screening.
  • Diagnosis of Central or Mixed Sleep Apnea with proportion of mixed or central apneas/hypopneas ≥ 50%, and/or diagnosis of Cheyne Stokes Respiration.
  • Active device treatment of OSA other than PAP therapy (eg, oral appliances), or other treatments, that in the opinion of the investigator, may interfere with study outcomes.
  • Respiratory diseases such as obesity hypoventilation syndrome or daytime hypercapnia, or neuromuscular diseases such as myasthenia gravis or other conditions that could interfere with the results of the trial in the opinion of the investigator.
  • Have personal circumstances or job-related responsibilities that prevent a 7-day PAP withdrawal before polysomnography testing during the course of the trial.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
250 participants (estimated)

Study arms

  • Experimental
    Maridebart Cafraglutide

    Participants will receive maridebart cafraglutide subcutaneously (SC).

    Drug: Maridebart cafraglutide

  • Placebo comparator
    Placebo

    Participants will receive placebo SC.

    Drug: Placebo

Interventions

  • Participants will receive maridebart cafraglutide as SC injections.

    Also known as: AMG 133

  • DrugPlacebo

    Participants will receive placebo SC.

06

What researchers measure

Primary outcomes

  1. Change in Apnea-Hypopnea Index (AHI) from baseline at week 52

    Time frame: At week 52

Secondary outcomes

  1. Percentage Change in AHI from baseline at week 52

    Time frame: At week 52

  2. Participants Achieving ≥ 50% AHI Reduction from baseline at week 52

    Time frame: At week 52

  3. Participants Achieving AHI < 5 or AHI 5 to 14 with Epworth Sleepiness Scale (ESS) ≤ 10 from baseline at week 52

    Time frame: At week 52

  4. Percentage Change in Body Weight from baseline at week 52

    Time frame: At week 52

  5. Change in Sleep Apnea-specific Hypoxic Burden (SASHB) from baseline at week 52

    Time frame: At week 52

  6. Percentage change in High Sensitivity C-reactive Protein (hs-CRP) from baseline at week 52

    Time frame: At week 52

  7. Change in Systolic Blood Pressure from baseline at week 48

    Time frame: At week 48

  8. Change in Patient-Reported Outcomes Measurement Information System (PROMIS) Short Form v1.0 Sleep-related Impairment 8a Score from baseline at week 52

    Time frame: At week 52

  9. Change in AHI from baseline at week 24

    Time frame: At week 24

  10. Percentage change in AHI from baseline at week 24

    Time frame: At week 24

  11. Change in SASHB from baseline at week 24

    Time frame: At week 24

  12. Change in ESS score from baseline at week 52

    Time frame: At week 52

  13. Change in PROMIS Short Form v1.0 Sleep Disturbance 8b score from baseline at week 52

    Time frame: At week 52

  14. Change in Short Form-36 Health Survey Version 2 (SF-36v2) Acute domain and summary scores from baseline at week 52

    Time frame: At week 52

  15. Change from baseline at week 52 in Patient Global Impression of Severity (PGI-S) Sleep-related impairment, Sleep quality, and Sleepiness.

    Time frame: At week 52

  16. Percentage of participants achieving ≥ 10% reduction in body weight from baseline at week 52

    Time frame: At week 52

  17. Percentage of participants achieving ≥ 15% reduction in body weight from baseline at week 52

    Time frame: At week 52

  18. Percentage of participants achieving ≥ 20% reduction in body weight from baseline at week 52

    Time frame: At week 52

  19. Change in waist circumference from baseline at week 52

    Time frame: At week 52

  20. Change in waist-to-height ratio from baseline at week 52

    Time frame: At week 52

  21. Change in neck circumference from baseline at week 52

    Time frame: At week 52

  22. Percentage change in Total Cholesterol, High-density lipoprotein cholesterol (HDL-C), Non-HDL-C, Low-density lipoprotein cholesterol (LDL-C), and Triglycerides from baseline at week 52 in fasting conditions

    Time frame: At week 52

  23. Percent change from baseline at week 52 in fasting insulin

    Time frame: At week 52

  24. Change from baseline at week 52 in fasting plasma glucose (FPG) (mg/dL, mmol/L)

    Time frame: At week 52

  25. Change in hemoglobin A1c (HbA1c) (%, mmol/mol) from baseline at week 52

    Time frame: At week 52

  26. Change in Diastolic Blood Pressure (DBP) from baseline at week 48

    Time frame: At week 48

  27. Number of participants with Treatment-Emergent Adverse Events and Serious Adverse Events

    Time frame: Up to 100 weeks

  28. Plasma concentration of maridebart cafraglutide at week 52

    Time frame: At week 52

07

Study locations

61 sites
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Aug 2027, 20 months after the start.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's planned 20 months is close to that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 6, 2026: primary completion Sep 2027 → Aug 2027 and completion Aug 2028 → Jul 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2025
First posted
Nov 10, 2025
StartActual
Dec 19, 2025
Primary completionEst.
Aug 20, 2027was Sep 2027
CompletionEst.
Jul 21, 2028was Aug 2028
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 3, 2027→Aug 20, 2027
Oct 6, 2026
Study completion
Aug 18, 2028→Jul 21, 2028
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Primary completion Sep 3, 2027→Aug 20, 2027
    Study completion Aug 18, 2028→Jul 21, 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07225686
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Nov 10, 2025
Start date
Dec 19, 2025
Primary completion
Aug 20, 2027 (estimated)
Completion
Jul 21, 2028 (estimated)
Last update
Oct 6, 2026

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Maridebart cafraglutide

Start the discussion